About Spruce Biosciences
Spruce Biosciences, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapies for endocrine disorders. The Company's development product candidate, tildacerfont, is a non-steroidal therapy that offers disease control for patients suffering from congenital adrenal hyperplasia (CAH). Tildacerfont is a non-steroidal, oral antagonist of the corticotropin-releasing hormone receptor 1 (CRF1) receptor, which is the receptor for corticotropin-releasing factor (CRF). By blocking the CRF1 receptor, tildacerfont enables to address the uncontrolled cortisol feedback regulatory pathway in CAH and reduce the production of adrenocorticotropic hormone (ACTH) in the pituitary, limiting the amount of androgen produced downstream from the adrenal gland. Tildacerfont also enables treating physicians to lower the supraphysiologic glucocorticoid doses given to CAH patients to near physiologic levels.